Infectious Disease · Medical Literature
[Articles] VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trial
Abstract
VRON-0200 alone or with investigational antiviral agents had no observed safety concerns and was well tolerated. Despite not targeting HBsAg, a single VRON-0200 dose induced broad and sustained anti-HBV immunity in most participants. When combined with antivirals, rapid and profound HBsAg declines were observed in all participants. This novel approach, in which anti-HBV immunity is sparked (ie, primed) with VRON-0200 and then fanned (ie, boosted) by HBV removal, could position VRON-0200 as a key agent for a future HBV functional cure.
Clinical relevance
In adults with chronic HBV infection receiving stable nucleos(t)ide therapy, is VRON-0200 — a novel checkpoint-modifier-containing immunotherapy — safe, tolerable, and capable of inducing durable anti-HBV immunity and HBsAg reduction, alone or in combination with investigational antiviral agents? __SNAPSHOT__ {"studyDesign":"Phase 1b, randomised, open-label, multicentre trial","setting":"Three centres in Hong Kong and New Zealand; multicentre international trial","sampleSize":"n=35 total (Groups 1 and 2: n=27; Group 3: n=8); 34 completed the study (1 withdrew consent on Day 28 for personal reasons)","population":"Adults aged 18–55 years with chronic HBV infection, normal liver function, receiving stable nucleos(t)ide therapy, and with non-detectable HBV DNA for ≥12 months. Median age 45–51 years; 80% male; 86% Asian; 97% HBeAg-negative; all believed to have acquired HBV perinatally. Median baseline HBsAg: Group 1 = 179 IU/mL (range 16–623), Group 2 = 149 IU/mL (range 10–563), Group 3 = 469 IU/mL (range 12–1169). Group 3 restricted to baseline HBsAg <1,000 IU/mL.","intervention":"VRON-0200 — a first-in-class immunotherapy comprising: (1) optimised HBV core and polymerase antigens (not surface antigen), covering genotypes A–D; (2) a herpes simplex virus-1 glycoprotein D (gD) checkpoint modifier fused to these antigens; and (3) a replication-defective chimpanzee adenoviral vector platform (AdC7 for prime, AdC6 for boost). Administered as a single intramuscular injection, with or without a boost dose. Groups 1a/1b: low-dose VRON-0200 (prime alone vs. prime–boost). Groups 2a/2b: high-dose VRON-0200 (prime alone vs. prime–boost). Group 3a/3b: VRON-0200 prime followed by six monthly doses of elebsiran plus tobevibart (starting Day 28), with or without a VRON-0200 boost on Day 196.","comparator":"Within-group randomisation to prime alone vs. prime–boost regimen (Groups 1 and 2); Group 3 randomised to VRON-0200 + elebsiran/tobevibart with or without a VRON-0200 boost. No placebo or sham-injection control arm.","primaryOutcome":"Safety and tolerability of VRON-0200. Secondary/exploratory: immunogenicity (IFN-γ ELISpot), and virological activity (HBsAg and HBV DNA levels).","followUp":"End-of-study Day 360 (one year); HBsAg declines observed without rebound up to 2+ years post-dosing per concurrent press disclosures (longer-term data presented at EASL 2026).","fundingSource":"Industry (Virion Therapeutics, LLC — a clinical-stage biotechnology company and the developer of VRON-0200)"}
Key findings
Primary safety endpoint: No serious treatment-related adverse events, treatment discontinuations, or treatment-related laboratory abnormalities were reported across all 35 participants; VRON-0200 was described as well tolerated in all arms. Immunogenicity: A single VRON-0200 prime dose induced broad, HBV-specific IFN-γ ELISpot responses in the majority of participants, consistent with restoration of CD8+ T-cell–mediated anti-HBV immunity. Specific ELISpot magnitudes, confidence intervals, and p-values are not reported in the available abstract. Virological activity (monotherapy, Groups 1–2): 23 of 27 participants (85%) in the VRON-0200 monotherapy groups experienced sustained or continuing HBsAg declines at Day 360 without rebound, despite VRON-0200 not targeting HBsAg directly. HBsAg declines were sustained or deepened up to 2+ years after the single dose per extended follow-up data presented at EASL 2026 (precise magnitude and absolute decline values not reported in the available abstract). Virological activity (combination arm, Group 3): All 8 participants receiving VRON-0200 plus elebsiran/tobevibart experienced rapid and profound HBsAg declines; HBsAg decline was sustained up to 3 months after the last dose of investigational antivirals. Absolute HBsAg decline values, p-values, and confidence intervals for virological outcomes are not reported in the available abstract. NNT and NNH cannot be calculated from abstract-level data. Note: All calculated or extrapolated values above are derived from publicly reported summary figures; individual-patient or inferential statistics are not available from the abstract alone.
Practice implications
This phase 1b trial establishes that VRON-0200 has an acceptable early safety and tolerability profile and can induce durable HBV-specific T-cell immunity and sustained HBsAg decline in a majority of virologically suppressed chronic HBV patients on nucleos(t)ide therapy. The mechanistic novelty lies in its checkpoint modifier (HSV-1 gD), which lowers the CD8+ T-cell activation threshold without targeting HBsAg directly — a departure from prior immunotherapy approaches. The combination arm data (n=8) suggest additive or synergistic antiviral activity with elebsiran (siRNA) and tobevibart (monoclonal antibody), consistent with the 'Spark and Fan' rationale. However, the study was not powered to establish efficacy; the sample size is very small (n=35 overall; n=8 in the combination arm), there is no placebo control, and all efficacy outcomes must be considered preliminary and hypothesis-generating. The study population was predominantly male, Asian, HBeAg-negative, perinatally infected, and had relatively low baseline HBsAg levels (<1,000 IU/mL in Group 3), limiting generalizability to HBeAg-positive patients, those with higher viral antigen burdens, non-Asian populations, and those with advanced fibrosis or cirrhosis. Functional cure (HBsAg loss sustained ≥6 months off all therapy) was not achieved or reported as an endpoint in this phase 1b study, and antiviral durability after treatment discontinuation remains to be formally tested in adequately powered trials. Practice should not change based on these data; a planned Phase 2b SPARK-B trial will be the critical next step. Only the abstract and concurrent press materials were available for this summary, limiting granular assessment of statistical methodology, blinding procedures, and adverse event characterisation. __LIMITATIONS__ Very small sample size (n=35 overall; n=8 in the combination arm), with no power calculation reported for efficacy endpoints.,Open-label design with no placebo or active comparator control arm, introducing performance and detection bias for subjective and exploratory endpoints.,Industry-sponsored trial (Virion Therapeutics is the developer), with associated risk of reporting and design bias.,Highly selected population: aged 18–55, normal liver function, HBV DNA suppressed ≥12 months, predominantly HBeAg-negative and of Asian race — markedly limits generalisability.,Restriction of Group 3 (combination arm) to baseline HBsAg <1,000 IU/mL excludes a substantial proportion of real-world chronic HBV patients.,Primary outcome is safety/tolerability; all virological and immunological outcomes are secondary/exploratory and must be interpreted accordingly — no pre-specified efficacy threshold was reported.,Surrogate endpoints only (HBsAg decline, IFN-γ ELISpot): no HBsAg loss, seroconversion, or off-treatment durability (functional cure) outcomes reported.,Absence of reported p-values, confidence intervals, or absolute effect sizes for virological endpoints in the publicly available abstract precludes formal statistical appraisal.,Only an abstract and press release materials were available; full paper data (adverse event tables, dose-response analysis, ELISpot kinetics) could not be independently verified.,Both investigational combination partners (elebsiran, tobevibart) are themselves unapproved, making it impossible to isolate VRON-0200's independent contribution in Group 3. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ VRON-0200, a first-in-class checkpoint-modifier immunotherapy targeting HBV core and polymerase antigens, demonstrated an acceptable safety profile and induced sustained HBsAg declines without rebound in 85% of virologically suppressed chronic HBV patients at one year after a single dose; rapid and profound HBsAg declines were observed in all 8 participants when combined with investigational antivirals elebsiran and tobevibart. These are early-phase, open-label, uncontrolled signals in a small, highly selected cohort — they are hypothesis-generating and not practice-changing. Clinicians should await results of the planned Phase 2b SPARK-B trial before integrating this approach into clinical decision-making.